Application of cytrodast in preparation of medicine for inhibiting osteoclast generation

By downregulating PPARγ and PPARGC1B-mediated fatty acid β oxidation and regulating ACSL1-mediated mitochondrial respiration metabolism, inhibiting osteoclast production, the problem that existing rheumatoid arthritis treatment drugs cannot prevent bone erosion is solved, and the problem of existing rheumatoid arthritis treatment drugs can be achieved. Effective bone destruction inhibition and improvement of the disease.

CN119015269APending Publication Date: 2024-11-26GUANGDONG HOSPITAL OF TRADITIONAL CHINESE MEDICINE
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411153284.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-21
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

Existing rheumatoid arthritis treatment drugs cannot effectively prevent bone erosion and have great side effects. Long-term use will lead to recurrence and aggravation of the disease. Some patients do not respond to these drugs or still experience persistent disability after remission.

Method used

Seratrodast (STD) is used as a drug to inhibit osteoclast production to prepare for the prevention and treatment of rheumatoid joints by downregulating PPARγ and PPARGC1B-mediated fatty acid beta oxidation and regulation of ACSL1-mediated mitochondrial respiration metabolism. Bone damage caused by inflammation.

Benefits of technology

It significantly inhibits the differentiation of macrophages into osteoclasts, reduces the production of osteoclasts, effectively reduces joint bone destruction, and improves the condition of rheumatoid arthritis. It provides a new drug for the treatment of rheumatoid arthritis.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005004208570000021
    Figure BDA0005004208570000021
  • Figure BDA0005004208570000022
    Figure BDA0005004208570000022
  • Figure BDA0005004208570000031
    Figure BDA0005004208570000031
Patent Text Reader

Abstract

The invention relates to the field of medicine application, in particular to application of cytrocalast in preparation of a medicine for inhibiting osteoclast generation. According to the application, cell experiments confirm that the cytrokast can remarkably inhibit differentiation of macrophages to osteoclasts, animal experiments confirm that the cytrokast can effectively reduce generation of osteoclasts of CIA model mice and inhibit bone destruction of joints, and therefore it is prompted that the cytrokast can effectively treat rheumatoid arthritis. Therefore, the cytrokast can be used for preparing a medicine for inhibiting osteoclast generation and a medicine for preventing and / or treating rheumatoid arthritis.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of drug application, and in particular to the application of serotonin in the preparation of drugs for inhibiting osteoclastogenesis. Background Art

[0002] Rheumatoid arthritis (RA) is a chronic autoimmune disease with the main clinical manifestations of synovitis, cartilage damage and symmetrical joint damage. RA is prone to small joints such as the hands and feet, and can also affect other systems outside the joints, and even lead to joint deformities and loss of function. The prevalence of rheumatoid arthritis is 5% to 10%, with regional differences. Women are more susceptible to the disease than men, and the functional disability of RA patients will reduce their work ability and social participation, increase medical expenses, and thus increase the social burden.

[0003] Bone destruction is the direct cause of RA joint deformity and is also a difficult problem in current clinical treatment. Although there is no method that can completely cure RA and its bone destruction, early diagnosis, early intervention and early treatment can more effectively control the disease and improve the quality of life of patients. Currently, the drugs for treating RA mainly include small molecule therapeutic drugs, such as nonsteroidal anti-inflammatory drugs (NSAIDs); glucocorticoids and other chemical synthetic antirheumatic drugs (DMARDs); biological macromolecule therapeutic drugs, such as tumor necrosis factor α inhibitors, B cell inhibitors, cytokine receptor inhibitors, target nuclear factor κB receptor activator ligand (RANKL) biological agents, and target granulocyte-macrophage colony stimulating factor biological agents. However, the above-mentioned drugs for treating RA all have large side effects, and long-term use will lead to recurrence and aggravation of the disease. Moreover, they can only alleviate the symptoms of RA but cannot prevent the progression of the disease. In particular, a considerable proportion of RA patients still do not respond to the above-mentioned therapeutic drugs, or still experience persistent disability after clinical remission. Therefore, there is an urgent need to develop drugs that can target and reverse bone erosion to treat and improve rheumatoid arthritis bone destruction. Summary of the invention

[0004] The purpose of the present invention is to provide a new use of serotonin, namely, for preparing a drug for inhibiting osteoclastogenesis.

[0005] The present invention is achieved through the following technical solutions:

[0006] According to the first aspect of the present invention, a new use of serotastat is provided, namely, use of serotastat in the preparation of a drug for inhibiting osteoclastogenesis, wherein the structural formula of serotastat is:

[0007]

[0008] In some embodiments, the drug that inhibits osteoclastogenesis acts by downregulating PPARγ and PPARGC1B-mediated fatty acid β-oxidation.

[0009] In some embodiments, the mechanism of action of the drug that inhibits osteoclastogenesis is to regulate ACSL1-mediated mitochondrial respiratory metabolism through PPARγ and PPARGC1B.

[0010] In some embodiments, the drug for inhibiting osteoclastogenesis further comprises a pharmaceutically acceptable excipient.

[0011] In some embodiments, the auxiliary material includes at least one of a pharmaceutically used carrier, an excipient, and a diluent.

[0012] In some embodiments, the drug for inhibiting osteoclastogenesis is in the form of capsules, granules, tablets or oral solutions.

[0013] According to the second aspect of the present invention, a new use of serostat is provided, namely, use of serostat as a drug for inhibiting osteoclastogenesis in the preparation of a drug for preventing and / or treating rheumatoid arthritis, wherein the structural formula of serostat is:

[0014]

[0015] In some embodiments, the drug for preventing and / or treating rheumatoid arthritis further comprises a pharmaceutically acceptable excipient.

[0016] In some embodiments, the auxiliary material includes at least one of a pharmaceutically used carrier, an excipient, and a diluent.

[0017] In some embodiments, the drug for preventing and / or treating arthritis is in the form of capsules, granules, tablets or oral liquids.

[0018] According to the third aspect of the present invention, a new use of serostat is provided, namely, use of serostat as a drug for inhibiting osteoclastogenesis in the preparation of a drug for preventing and / or treating bone destruction caused by rheumatoid arthritis, wherein the structural formula of serostat is:

[0019]

[0020] The beneficial effects of the present invention include:

[0021] (1) The present invention confirms through cell experiments that serostat can significantly inhibit the differentiation of macrophages into osteoclasts; serostat reduces osteoclastogenesis by downregulating fatty acid β-oxidation mediated by PPARγ and PPARGC1B; serostat regulates ACSL1-mediated mitochondrial respiratory metabolism through PPARγ and PPARGC1B, and ultimately inhibits osteoclastogenesis. Therefore, serostat can be used to prepare drugs that inhibit osteoclastogenesis.

[0022] (2) The present invention has confirmed through animal experiments that serostat can effectively reduce the production of osteoclasts in CIA model mice and inhibit bone destruction in joints, thereby suggesting that serostat can effectively treat rheumatoid arthritis. Therefore, serostat can be used to prepare drugs for preventing and / or treating rheumatoid arthritis. BRIEF DESCRIPTION OF THE DRAWINGS

[0023] Figure 1 This is the experimental result of STD inhibiting osteoclast differentiation of macrophages in the cell experiment of the present invention. In the figure, P<0.05 indicates that the difference is significant.

[0024] Figure 2 This is the experimental result of the cell experiment of the present invention that STD reduces osteoclastogenesis by down-regulating fatty acid β-oxidation mediated by PPARγ and PPARGC1B. In the figure, P<0.05 indicates that the difference is significant.

[0025] Figure 3 This is the experimental result of the cell experiment of the present invention, in which STD inhibits osteoclastogenesis by regulating ACSL1-mediated mitochondrial respiratory metabolism through PPARγ and PPARGC1B. In the figure, P<0.05 indicates that the difference is significant.

[0026] Figure 4 This is the experimental result of STD inhibiting bone destruction in arthritis mice in the animal experiment of the present invention. In the figure, P<0.05 indicates that the difference is significant. DETAILED DESCRIPTION

[0027] The present invention is further described in detail below with reference to the accompanying drawings. Unless otherwise specified, the reagents used in the following tests are all commercially available, and the experimental methods not otherwise specified are all conventional methods known in the art.

[0028] The thromboxane A2 (TXA2) pathway, mainly including TXA2 synthase (TBXAS1), TXA2 receptor (TP) and cyclooxygenase-2 (COX-2), is associated with osteoclast differentiation and bone destruction. 9,11-epoxy-11,12-methylthromboxane A2, a stable analog of TXA2, can affect bone destruction in vitro and in vivo by directly promoting osteoclast formation or accelerating bone resorption. In addition, COX-2 selective antagonists can inhibit osteoclast formation, while specific TBXAS1 inhibitors can regulate the expression of TNFSF11 and TNFRSF11B encoding RANKL and osteoprotegerin (OPG) in osteoblasts. However, the specific mechanism by which the TXA2 pathway affects bone destruction, especially in rheumatoid arthritis, remains unclear. Therefore, based on the important role of the TXA2 pathway in bone destruction and its potential therapeutic prospects, the present invention studies the effect of the TXA2 receptor inhibitor Seratrodast (STD) on bone destruction in rheumatoid arthritis.

[0029] Seratrodast (STD) is an orally effective thromboxane A2 receptor inhibitor developed by TAP, a joint venture between Takeda of Japan and Abbott of the United States, for the treatment of bronchial asthma. The structural formula of STD is:

[0030]

[0031] First, to verify the role of STD in inhibiting osteoclastogenesis, the following cell experiments were performed.

[0032] 1. Purpose of the experiment

[0033] Through in vitro cell experiments, (1) we explored the effects of thromboxane and key molecules in its pathway on macrophage osteoclast differentiation; and (2) we studied the molecular mechanism by which STD inhibits osteoclastogenesis.

[0034] 2. Experimental Methods

[0035] 1. Cell culture

[0036] Isolation and culture of bone marrow macrophages (BMMs): BMMs were isolated from the bone marrow of 6-8 week-old C57BL / 6 male mice and cultured at 1.5×10 6Cells / mL were seeded in 12-well or 6-well plates. α-MEM medium (Gibco, Cat#C12571500BT) containing 10% fetal bovine serum (FBS, Sigma-Aldrich, Cat#F8318-500ML), 1% penicillin / streptomycin (Gibco, Cat#15140122), and 30ng / ml mouse macrophage colony stimulating factor (M-CSF, R&D Systems, Cat#416-ML-010) was used for 3 days. After 3 days, the adherent cells were removed to obtain osteoclast precursor cells. Subsequently, in order to induce osteoclast differentiation, α-MEM medium containing 30ng / mL M-CSF and 50ng / mL mouse nuclear factor κB receptor activator ligand (RANKL, R&D Systems, Cat#462-TEC-010) was used for culture. For experiments involving the thromboxane A2 receptor (TBXA2R) inhibitor Seratrodast (STD), the thromboxane synthase inhibitor Ozagrel (OZ) and the thromboxane A2 mimetic (CTA2), 75 μM or 150 μM STD (Selleck, Cat#S2072), 150 μM OZ (Selleck, Cat#S2496) or different concentrations of CTA2 (1 μM, 5 μM, 10 μM; Cayman, Cat#19010) were added, respectively. The culture medium was changed every two days, and mature osteoclasts were formed in the M-CSF and RANKL combined intervention group within 6-7 days and in the CTA2 intervention group within 10-12 days. Osteoclasts were fixed and stained using an acid phosphatase (TRAP) staining kit (Wako, Cat#294-67001). TRAP-positive multinucleated cells containing three or more nuclei were counted using an inverted microscope.

[0037] The specific experimental grouping information is as follows:

[0038] (1) Ctrl group: 30 ng / mL M-CSF

[0039] (2)M+R(Model) group: 30ng / mL M-CSF+50ng / mL RANKL

[0040] (3)STD-L group: 30ng / mL M-CSF+50ng / mL RANKL+75μM STD

[0041] (4) STD-H (STD) group: 30ng / mL M-CSF+50ng / mL RANKL+150μM STD

[0042] (5)OZ group: 30ng / mL M-CSF+50ng / mL RANKL+150μM OZ

[0043] (6) CTA2 1μM group: 30ng / mL M-CSF + 1μM CTA2

[0044] (7) CTA2 5μM group: 30ng / mL M-CSF + 5μM CTA2

[0045] (8) CTA2 10 μM group: 30 ng / mL M-CSF + 10 μM CTA2

[0046] 2. Quantitative Real-Time PCR

[0047] RNA extraction and reverse transcription: BMMs were isolated from the bone marrow of C57BL / 6 male mice, and total RNA was extracted using the EZ-press RNA Purification Kit (EZBioscience, Cat#B0004D) on day 4 of induction of osteoclast differentiation. Total RNA (500 ng) was reverse transcribed into cDNA using Vazyme III RT SuperMix for qPCR (with gDNA eraser) (Vazyme, Cat# R323-01).

[0048] Real-time PCR detection: Fast ChamQ Universal SYBR qPCR Master Mix (Vazyme, Cat# R323-01) was used in ABI ViiA TM Real-time PCR detection was performed on a 7-real-time PCR detection system (Life Technologies). The primer sequences for quantitative real-time PCR are shown in Table 1.

[0049] Table 1 Primer sequences for quantitative real-time PCR

[0050] Gene Forward primer sequence Reverse primer sequence Cs GGACAATTTTCCAACCAATCTGC TCGGTTCATTCCCTCTGCATA Aco2 ATCGAGCGGGGAAAGACATAC TGATGGTACAGCCACCTTAGG β-actin AAGGCCAACCGTGAAAAGAT GTGGTACGACCAGAGGCATAC Acsl1 TGCCAGAGCTGATTGACATTC GGCATACCAGAAGGTGGTGAG Acp5 GATGCCAGCGACAAGAGGTT CATACCAGGGGATGTTGCGAA Fos CGGGTTTCAACGCCGACTA TTGGCACTAGAGACGGACAGA Car2 CTCAGTGACTCCTACAGATTGATCC GGTGTTCCAGTGAACCAAGTGAA Calcr CCTGGACTGAGATGACTGTGTTC CTCAACGGTACAAATGGCTCAA

[0051] 3. Bulk RNAseq

[0052] RNA extraction and quality testing: BMMs were isolated from the bone marrow of C57BL / 6 male mice and used on day 4 of induction of osteoclast differentiation. Total RNA was extracted using ELISA kit (Magen), and the purity and integrity were assessed by Nanodrop ND-2000 system (ThermoScientific) and Agilent Bioanalyzer 4150 (Agilent Technologies).

[0053] Library construction and sequencing: Paired-end libraries were prepared using the ABclonal mRNA-seq Lib Prep Kit (ABclonal). Library quality was verified on an Agilent Bioanalyzer 4150, and 150 bp paired-end sequencing was performed on an Illumina Novaseq 6000. The sequencing results were analyzed by bioinformatics.

[0054] 4. Acetyl CoA Determination

[0055] Sample preparation and detection: BMMs were isolated from the bone marrow of C57BL / 6 male mice, and cells were lysed and collected using protein lysis buffer on day 4 of induction of osteoclast differentiation. Samples lysed with protein lysis buffer were used to measure acetyl-CoA levels in 96-well microplates using a commercial fluorescence assay kit (Sigma-Aldrich, Cat#MAK039) according to the manufacturer's instructions. Fluorescence intensity was measured at Ex / Em=535 / 587nm, and the acetyl-CoA content in the sample was calculated using the acetyl-CoA standard curve.

[0056] 5. Targeted metabolomics

[0057] Sample processing and chromatographic separation: BMMs were isolated from the bone marrow of C57BL / 6 male mice. On the 4th day of induction of osteoclast differentiation, the culture medium was removed and washed twice with ice-cold PBS, and then washed once with ice-cold saline (0.9% sodium chloride solution). The supernatant was completely discarded after each wash. A mixture of methanol (Merck, Cat#144282), acetonitrile (Merck, Cat#1499230-935) and water (2:2:1, v / v) was added, vortexed for 60 seconds, and sonicated at 4°C for 30 minutes, and repeated twice. The sample was incubated at -20°C for 1 hour to precipitate the protein, and then centrifuged at 14,000rcf and 4°C for 20 minutes. The supernatant was freeze-dried for analysis.

[0058] The samples were separated using an Agilent 1290 Infinity LC ultra-high performance liquid chromatography system (Agilent Technologies). Mobile phase: Liquid A was a 10 mM ammonium acetate aqueous solution, and liquid B was acetonitrile. The sample was placed in an automatic sampler at 4°C, the column temperature was 45°C, the flow rate was 300 μL / min, and the injection volume was 2 μL. The mobile phase gradient was set as follows: 0-18 min, liquid B changed linearly from 90% to 40%; 18-18.1 min, liquid B changed linearly from 40% to 90%; 18.1-23 min, liquid B was maintained at 90%. A QC sample was set for every certain number of experimental samples in the sample queue to detect and evaluate the stability and repeatability of the system; a standard mixture of energy metabolites was set in the sample queue for correction of chromatographic retention time. Mass spectrometry analysis was performed using a 5500QTRAP mass spectrometer (AB SCIEX) in negative ion mode. The 5500QTRAP ESI source conditions were set as follows: source temperature 450°C, ion Source Gas1 (Gas1): 45, Ion Source Gas2 (Gas2): 45, Curtain gas (CUR): 30, ion Sapary Voltage Floating (ISVF) -4500V. The MRM mode was used to detect the ion pairs to be tested. The chromatographic peak area and retention time were extracted using Multiquant software. The retention time was corrected using standard samples of energy metabolites for metabolite identification.

[0059] 6. Seahorse XF24 Respirometry

[0060] Oxygen consumption rate (OCR) assay: BMMs cells (1×10 5Each well) was inoculated in a Seahorse XF24 cell culture microplate (Agilent, Cat#102340-100), and 200 μL of culture medium was used in each well. The culture medium was XF basic medium (pH=7.4) (Agilent, Cat#103575-100) supplemented with pyruvate (100 mM) (Agilent, Cat#103578-100), glutamine (200 mM) (Agilent, Cat#103579-100) and glucose (2.5 M) (Agilent, Cat#103577-100). The cells were treated under the conditions of M-CSF, RANKL and STD, and the treatment method was the same as described above. OCR was measured on days 2 and 4 of osteoclast differentiation using a Seahorse XF24 Cell Energy Metabolism Analyzer (Seahorse Bioscience) and a Mitochondrial Stress Test Kit (Agilent, Cat# 103015-100) according to the manufacturer's instructions. OCR values ​​were normalized to the protein concentration of each well.

[0061] 7. Western Blot Analysis

[0062] Protein extraction and electrophoresis: The cells cultured in different treatment groups were lysed on ice with lysis buffer containing protease and phosphatase inhibitors. The protein samples were heat denatured and lysed, separated by SDS-PAGE, and wet transferred to PVDF membranes. After blocking with TBST (containing Tris-HCl, NaCl and tween20) containing 5% skim milk powder for 120 minutes, the membrane was incubated with the primary antibody (as shown in Table 2) at 4°C overnight. Subsequently, the membrane was incubated with horseradish peroxidase (HRP)-labeled goat anti-rabbit IgG (H+L) secondary antibody (CST, 1:2000, #7074S) at room temperature for 1 hour. After adding the chemiluminescent reagent, the PVDF membrane was exposed to X-ray film in a dark room. The gray value of the bands was analyzed to compare the differences between the groups.

[0063] Table 2 Primary antibodies used in the experiments

[0064]

[0065]

[0066] 3. Experimental Results

[0067] 1. STD can inhibit macrophage osteoclast differentiation

[0068] The present invention uses different concentrations of TXA2 mimetic CTA2 (1 μM, 5 μM and 10 μM) combined with M-CSF to stimulate primary mouse bone marrow macrophages (BMMs) to explore their effects on osteoclast formation. The experimental results show that different concentrations of CTA2 can induce the formation of osteoclasts ( Figure 1 A). The thromboxane A2 receptor (TBXA2R) inhibitor Seratrodast (STD) and the thromboxane synthase (TBXAS1) inhibitor Ozagrel (OZ) were further used to clarify the effect of the thromboxane pathway on osteoclast differentiation. The results showed that both can effectively inhibit osteoclast differentiation, among which STD has a particularly significant inhibitory effect on osteoclast differentiation ( Figure 1 B). Further PCR results showed that STD could significantly inhibit the expression of osteoclast-specific genes Acp5, Fos, Car2 and Calcr ( Figure 1 C).

[0069] Conclusion: STD can significantly inhibit the differentiation of macrophages into osteoclasts.

[0070] 2. STD reduces osteoclastogenesis by downregulating PPARγ and PPARGC1B-mediated fatty acid β-oxidation

[0071] Whole transcriptome RNA sequencing was used to explore the mechanism by which STD inhibits osteoclast differentiation. The results revealed 56 common gene ontology (GO) pathways that were upregulated in the model group and significantly inhibited after STD intervention. Most of the pathways were related to regulating bone destruction and bone resorption ( Figure 2 A. Figure 2 B). PPARγ coactivator 1β (PPARGC1B) is involved in regulating bone destruction and mitochondrial respiration, and the present invention found that PPARGC1B was significantly downregulated after STD intervention ( Figure 2 C. Figure 2 D). Furthermore, Western blot results showed that STD could significantly inhibit the protein expression of PPARGC1B and its upstream PPARγ ( Figure 2 E).

[0072] PPARγ and PPARGC1B regulate the transcription of long-chain fatty acid coenzyme synthase 1 (ACSL1) by binding to the promoter region of the gene. ACSL1 can be transported to the inside of the mitochondria and participate in the fatty acid β-oxidation metabolism process. The present invention investigated the effect of STD on ACSL1 at the transcriptional level and protein level. The results showed that STD can significantly inhibit the transcription and protein expression of ACSL1, especially at the 4th and 6th day of inducing osteoclast differentiation ( Figure 2F). Therefore, STD can downregulate PPARγ- and PPARGC1B-mediated fatty acid β-oxidation, thereby affecting fatty acid metabolism and cellular energy balance and alleviating osteoclastogenesis.

[0073] Conclusion: STD attenuates osteoclastogenesis by downregulating PPARγ- and PPARGC1B-mediated fatty acid β-oxidation.

[0074] 3. STD regulates ACSL1-mediated mitochondrial respiratory metabolism through PPARγ / PPARGC1B, ultimately inhibiting osteoclastogenesis

[0075] Previous studies have confirmed that STD can regulate fatty acid β-oxidation mediated by PPARγ and PPARGC1B. During the differentiation of macrophages into osteoclasts, there is high fatty acid β-oxidation metabolism and mitochondrial tricarboxylic acid cycle metabolism, and fatty acid β-oxidation metabolism is an important support for mitochondrial respiratory metabolism. Therefore, the inventors speculate that STD ultimately inhibits osteoclastogenesis by regulating mitochondrial respiratory metabolism mediated by fatty acid β-oxidation.

[0076] To verify the above hypothesis, the present invention investigated acetyl-coenzyme A (Acetyl-CoA), a metabolite of fatty acid β-oxidation and the starting substrate of mitochondrial tricarboxylic acid cycle metabolism. The results showed that Acetyl-CoA expression was increased in the RANKL-induced model group, and its expression level could be significantly inhibited after STD intervention ( Figure 3 A. Figure 3 B). We further used the energy metabolism group to study the effect of STD on the metabolites and metabolic enzymes related to the tricarboxylic acid cycle downstream of Acetyl-CoA, and found that STD can significantly inhibit the production of metabolites such as Citrate, cis-Aconitate, Isocitrate, and Malate in the tricarboxylic acid cycle pathway and the expression of CS and ACO2 metabolic enzymes upstream ( Figure 3 C. Figure 3 D. Figure 3 E). The hippocampal mitochondrial respiration experiment further confirmed that STD can inhibit the high mitochondrial respiration during osteoclast differentiation ( Figure 3 F).

[0077] Conclusion: In vitro cell experiments confirmed that STD regulates ACSL1-mediated mitochondrial respiratory metabolism through PPARγ / PPARGC1B, ultimately inhibiting osteoclastogenesis.

[0078] Then, to verify the efficacy of STD on rheumatoid arthritis, the following animal experiments were conducted.

[0079] 1. Purpose of the experiment

[0080] Previous in vitro cell experiments have confirmed that STD can inhibit osteoclastogenesis, but its effect in vivo needs further study. The following in vivo animal experiments were conducted to explore the effect of STD on the bone destruction process in mice with collagen-induced arthritis (CIA).

[0081] 2. Experimental Methods

[0082] 1. Grouping

[0083] Part of the mice used in the experiment were 6-8 week old male wild-type DBA / 1 mice purchased from Jiangsu Jicui Yaokang Biotechnology Co., Ltd. (Jiangsu, China). The other part of the mice were TBXA2R knockout mice constructed by Saiye Biotechnology Co., Ltd. (USA). The temperature of the mouse breeding room was 21±2℃ and the relative humidity was 55±5%. The mouse grouping information is as follows:

[0084] (1) Specific experimental grouping information involving STD drug intervention:

[0085] ① Blank control group (referred to as Ctrl group), 4 wild-type DBA / 1 mice without TBXA2R knockout;

[0086] ② Arthritis model group (referred to as CIA group), 5 wild-type DBA / 1 mice without TBXA2R knockout;

[0087] ③ Arthritis model + STD drug intervention group (referred to as STD group), 6 wild-type DBA / 1 mice without TBXA2R knockout.

[0088] (2) Specific experimental grouping information involving TBXA2R knockout:

[0089] ① Wild-type blank control group (abbreviated as WT-Ctrl group), 5 wild-type DBA / 1 mice without TBXA2R knockout;

[0090] ② Wild-type arthritis model group (abbreviated as WT-CIA group), 5 wild-type DBA / 1 mice without TBXA2R knockout;

[0091] ③TBXA2R knockout blank control group (referred to as TBXA2R-KO-Ctrl group), 4 TBXA2R knockout mice;

[0092] ④TBXA2R knockout arthritis model group (TBXA2R-KO-CIA group for short), 4 TBXA2R knockout mice.

[0093] 2. Modeling

[0094] Method for constructing a collagen-induced arthritis (CIA) mouse model: Bovine type II collagen (#20021; Chondrex) was completely dissolved with 0.1M acetic acid, and then emulsified overnight with an equal volume of complete Freund's adjuvant (#7009; Chondrex) to obtain a bovine type II collagen emulsion. Under sterile conditions, the tail base of the mouse was disinfected with alcohol, and then the prepared bovine type II collagen emulsion was intradermally injected at multiple points (3-4 points) at the tail base, with 100 μL injected into each mouse, and the injection points were spaced 0.5-1 cm apart.

[0095] The mice in the CIA group, STD group, WT-CIA group, and TBXA2R-KO-CIA group were subjected to CIA modeling according to the above method, and the mice in the remaining groups were not subjected to modeling treatment.

[0096] 3. Drug treatment

[0097] STD was dissolved in physiological saline containing 4% dimethyl sulfoxide (DMSO) to obtain a STD solution with a STD concentration of 10 mg / kg. After successful modeling, mice in the STD group were intraperitoneally injected with 0.2 mL of STD solution once a day for 3 consecutive weeks.

[0098] The mice in the other groups were intraperitoneally injected with an equal volume (0.2 mL) of normal saline containing 4% DMSO, once a day for 3 consecutive weeks.

[0099] After treatment, serum and ankle joints of mice were collected. Ankle joint tissues were sectioned and stained with hematoxylin-eosin (H&E) to determine pathological changes and cartilage erosion levels. TRAP staining was used to assess osteoclastogenesis. All animal experiments were conducted in accordance with the Chinese Laboratory Animal Welfare Ethics Review Guidelines and approved by the Experimental Animal Ethics Committee of Guangdong Provincial Hospital of Traditional Chinese Medicine.

[0100] 4. Enzyme-linked immunosorbent assay (ELISA)

[0101] TXB2 detection: Since TXA2 is unstable, its stable form TXB2 is usually detected. After 3 weeks of administration, blood samples were collected from each group and centrifuged at a rate of 3000min for 10min. The upper serum was taken and stored at -20°C for testing. Mouse TXB2 (thromboxane B2) ELISA kit (Elabscience, Catalog no.42073) was used for analysis according to the manufacturer's instructions. The absorbance was measured at 450nm using an enzyme reader (Thermo Fisher Scientific). The standard curve established by the standard provided by the kit was fitted by computer and the TXB2 concentration of each sample was automatically calculated.

[0102] 3. Experimental Results

[0103] By establishing a collagen-induced arthritis (CIA) mouse model, it was found that STD intervention could inhibit joint swelling in CIA mice ( Figure 4 A). The results of joint HE showed that compared with the Ctrl group, the CIA group had severe synovial tissue hyperplasia, accompanied by bone destruction and inflammatory cell infiltration; compared with the CIA group, the STD group had different degrees of improvement in synovial hyperplasia, bone destruction and inflammatory cell infiltration ( Figure 4 B). TRAP staining showed that compared with the Ctrl group, the CIA group had more osteoclast formation and bone destruction in the joints; compared with the CIA group, the STD group had less osteoclast formation and bone destruction in the joints, indicating that STD reduced the production of osteoclasts and improved bone destruction in the joints ( Figure 4 B).

[0104] We further constructed TBXA2R gene knockout mice to explore the effects of knockout TBXA2R gene on arthritis mice at the genetic level. The results of joint swelling measurements showed that TBXA2R gene knockout arthritis mice (TBXA2R-KO-CIA) were less likely to develop arthritis symptoms than wild-type arthritis mice (WT-CIA) under the same modeling conditions. Figure 4 C), and the results of small animal imaging showed that the TBXA2R-KO-CIA group of mice had milder bone destruction than the WT-CIA group of mice ( Figure 4 D). ELISA results showed that the TBXA2R-KO-CIA group mice had lower levels of plasma TxB2 than the WT-CIA group mice ( Figure 4 E). Joint HE and TRAP staining results showed that TBXA2R-KO-CIA mice had milder joint histopathological manifestations and less osteoclast formation than WT-CIA mice ( Figure 4 F).

[0105] Conclusion: In vivo animal experiments further confirmed that STD can inhibit bone destruction in CIA arthritis mice, suggesting that STD can effectively treat rheumatoid arthritis.

[0106] The above are only some embodiments of the present invention. For those skilled in the art, several modifications and improvements can be made without departing from the creative concept of the present invention, which all belong to the protection scope of the present invention.

Claims

1. Use of serostat in the preparation of drugs for inhibiting osteoclastogenesis, in, The structural formula of the serostat is:

2. The use according to claim 1, It is characterized in that The mechanism of action of the drug for inhibiting osteoclastogenesis is to down-regulate fatty acid β-oxidation mediated by PPARγ and PPARGC1B.

3. The use according to claim 2, It is characterized in that The mechanism of action of the drug for inhibiting osteoclastogenesis is to regulate ACSL1-mediated mitochondrial respiratory metabolism through PPARγ and PPARGC1B.

4. The use according to any one of claims 1 to 3, It is characterized in that The drug for inhibiting osteoclastogenesis also includes pharmaceutically acceptable excipients.

5. The use according to claim 4, It is characterized in that The auxiliary material includes at least one of a carrier, an excipient, and a diluent used in medicine.

6. The use according to any one of claims 1 to 3, It is characterized in that The dosage form of the drug for inhibiting osteoclastogenesis is capsule, granule, tablet or oral solution.

7. Use of serostat as a drug for inhibiting osteoclastogenesis in the preparation of a drug for preventing and / or treating rheumatoid arthritis, in, The structural formula of the serostat is:

8. The use according to claim 7, It is characterized in that The drug for preventing and / or treating rheumatoid arthritis also includes pharmaceutically acceptable excipients.

9. The use according to claim 8, It is characterized in that The auxiliary material includes at least one of a carrier, an excipient, and a diluent used in medicine.

10. Use of serotonin as a drug for inhibiting osteoclastogenesis in the preparation of a drug for preventing and / or treating bone destruction caused by rheumatoid arthritis, in, The structural formula of the serostat is: